title: Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure.
abstract: A total of 52 men, median age 55 years (range 28 to 74 years), with erectile failure was treated with vasoactive intestinal polypeptide and phentolamine. Impotence was classified as psychogenic in 3 patients, psychogenic/arteriogenic in 3, arteriogenic in 25, arteriogenic/neurogenic in 4, neurogenic in 5, venous leakage/psychogenic in 2, venous leakage/neurogenic in 1 and following venous leak surgery in 9. The patients were treated with 30 micrograms vasoactive intestinal polypeptide and 0.5 to 2.0 mg. phentolamine. A total of 1,380 self-injections was given and the number of injections per patient varied from 5 to 245. No patient had priapism, corporeal fibrosis or other serious complications. After sexual stimulation all patients obtained erection sufficient for penetration. Following ejaculation rigidity decreased normally. The median duration of treatment was 6 months (range 1 to 22). Nine patients discontinued treatment. One patient with severe arteriosclerosis experienced decreased effectiveness of the drug and received a penile prosthesis. Five patients elected not to perform self-injection any longer, 1 psychogenic impotent patient was cured, and 1 patient discontinued therapy due to palpitation and sweating. One patient died of a myocardial infarction not associated with this therapy.
authors.affiliation: Department of Urology, Herlev Hospital, Copenhagen, Denmark.
authors.forename: T C
authors.initials: TC
authors.lastname: Gerstenberg
authors.forename: P
authors.initials: P
authors.lastname: Metz
authors.forename: B
authors.initials: B
authors.lastname: Ottesen
authors.forename: J
authors.initials: J
authors.lastname: Fahrenkrug
mesh_terms: D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010646:Phentolamine / Q000008:administration & dosage* / Q000627:therapeutic use; D012646:Self Administration; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D014660:Vasoactive Intestinal Peptide; D010646:Phentolamine